Skip to main content
. 2021 Jul 4;5(3):e264–e272. doi: 10.1055/s-0041-1730283

Table 3. Analysis of bleeding characteristics and wilate treatment.

Population a Patients experiencing bleed,
n (%)
Number of bleeds Type Severity Treatment with wilate
Spontaneous,
n (%)
Trauma,
n (%)
Other/ unknown,
n (%)
Mild,
n (%)
Moderate,
n (%)
Severe,
n (%)
Unknown,
n (%)
1–2 infusions,
% ( n )
>2 infusions,
% ( n )
Infusions/treatment,
median (range)
Dose [IU/kg],
median (range)
Prophylaxis ( N  = 25) 18 (72.0) 233 154 (66.1) 42 (18.0) 37 (15.9) 87 (37.3) 103 (44.2) 20 (8.6) 23 (9.9) 85.1 (149/175) 14.9 (26/175) 1 (1–14) 55.4 (8.3–1441.3)
On-demand ( N  = 29) 25 (86.2) 150 102 (68.0) 31 (20.7) 17 (11.3) 27 (18.0) 107 (71.3) 15 (10.0) 0 (0) 94.2 (130/138) 5.8 (8/138) 1 (1–13) 33 (8.3–625)
Menstrual bleeding ( N  = 9) 9 (100) 56 5 (8.9) 20 (35.7) 26 (46.4) 5 (8.9) 46.4 (26/56) 53.6 (30/56) 3 (1–7) 79.1 (10–339.8)
a

Two patients changed from on-demand treatment to prophylaxis, and three patients changed from prophylaxis to on-demand treatment. For all analyses by treatment regimen, these five patients were included in both analysis populations. Seven patients treated on-demand and two treated prophylactically also received treatment for menstrual bleeding.